SOLICITATION NOTICE
Q -- COVID-19 Laboratory IVD (Diagnostics)
- Notice Date
- 5/6/2021 7:39:50 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- OFFICE OF ACQ MGMT POLICY WASHINGTON DC 20201 USA
- ZIP Code
- 20201
- Solicitation Number
- 75A50121R00037
- Response Due
- 5/13/2021 12:00:00 PM
- Archive Date
- 05/28/2021
- Point of Contact
- Jeffrey Schmidt, Phone: 202.205.0260
- E-Mail Address
-
jeffrey.schmidt2@hhs.gov
(jeffrey.schmidt2@hhs.gov)
- Small Business Set-Aside
- SBA Total Small Business Set-Aside (FAR 19.5)
- Description
- The Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS) seeks to fund the necessary activities and clinical evaluations so an organization can transition their over the counter COVID-19 diagnostic tests from EUA to 510(k) and CLIA waiver.� Among other things, the diagnostic test should be easy to use and not require external readers. See attached Combined Synopsis/Solicitation (CSS) for complete requirement details. The beta.sam.gov posting and the attached CSS was modifed at 10:40AM EDT, May 6, 2021 to remove reference to this being a requirements for a ""Molecular"" diagnostic test.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/f7ebc5723c964a4eaeb8c8e5d10abe47/view)
- Record
- SN05993704-F 20210508/210506230114 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |